1-3 of 3
Thomas F. Gajewski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Hongtao Liu, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher S. Hourigan, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Wendy Stock
Journal: Blood
Blood (2022) 140 (Supplement 1): 1716–1719.
https://doi.org/10.1182/blood-2022-157326
Published: 2022
Journal Articles

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

Long Zhang, Thomas F. Gajewski, Justin Kline
Journal: Blood
Blood (2009) 114 (8): 1545–1552.
https://doi.org/10.1182/blood-2009-03-206672
Published: 2009
Journal Articles

Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level

Reinhard E. Marks, Allen W. Ho, Christian Robbel, Todd Kuna, Seth Berk, Thomas F. Gajewski
Journal: Blood
Blood (2007) 110 (6): 1982–1988.
https://doi.org/10.1182/blood-2006-06-031088
Published: 2007